Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more
Seelos Therapeutics Inc (SEEL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.165x
Based on the latest financial reports, Seelos Therapeutics Inc (SEEL) has a cash flow conversion efficiency ratio of 0.165x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.64 Million) by net assets ($-28.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Seelos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1997–2023)
This chart illustrates how Seelos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Seelos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seelos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CVS GROUP
BE:4C9
|
N/A |
|
PT Perma Plasindo Tbk
JK:BINO
|
-0.017x |
|
MINEBEA (MEA.SG)
STU:MEA
|
0.053x |
|
RACL Geartech Limited
NSE:RACLGEAR
|
N/A |
|
SECURITAS -B- (S7MB.SG)
STU:S7MB
|
0.075x |
|
KYOCERA
MU:KYR
|
0.026x |
|
SFC ENERGY - Dusseldorf Stock Exchang
DU:F3C
|
0.047x |
|
Boss Holdings Inc
PINK:BSHI
|
0.062x |
Annual Cash Flow Conversion Efficiency for Seelos Therapeutics Inc (1997–2023)
The table below shows the annual cash flow conversion efficiency of Seelos Therapeutics Inc from 1997 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-33.51 Million | $-23.91 Million | 0.714x | -87.71% |
| 2022-12-31 | $-10.61 Million | $-61.60 Million | 5.806x | +779.25% |
| 2021-12-31 | $57.32 Million | $-48.99 Million | -0.855x | +89.49% |
| 2020-12-31 | $2.57 Million | $-20.91 Million | -8.131x | -100.29% |
| 2019-12-31 | $-7.00K | $-19.30 Million | 2757.857x | +87358.07% |
| 2018-12-31 | $2.57 Million | $-8.13 Million | -3.161x | -32.00% |
| 2017-12-31 | $4.37 Million | $-10.47 Million | -2.394x | -237.71% |
| 2016-12-31 | $-7.52 Million | $-13.07 Million | 1.739x | -23.64% |
| 2015-12-31 | $-9.94 Million | $-22.64 Million | 2.277x | +124.25% |
| 2014-12-31 | $1.92 Million | $-18.02 Million | -9.388x | -583.72% |
| 2013-12-31 | $10.97 Million | $-15.06 Million | -1.373x | +36.85% |
| 2012-12-31 | $6.62 Million | $-14.39 Million | -2.174x | -7.72% |
| 2011-12-31 | $4.82 Million | $-9.72 Million | -2.018x | -238.89% |
| 2010-12-31 | $11.57 Million | $-6.89 Million | -0.596x | +54.15% |
| 2009-12-31 | $2.71 Million | $-3.51 Million | -1.299x | +26.62% |
| 2008-12-31 | $1.53 Million | $-2.71 Million | -1.770x | -29.12% |
| 2007-12-31 | $4.80 Million | $-6.59 Million | -1.371x | -136.59% |
| 2006-12-31 | $11.50 Million | $-6.67 Million | -0.580x | +92.29% |
| 2005-12-31 | $1.31 Million | $-9.84 Million | -7.519x | -462.93% |
| 2004-12-31 | $11.40 Million | $-15.23 Million | -1.336x | -9.32% |
| 2003-12-31 | $12.72 Million | $-15.55 Million | -1.222x | +83.05% |
| 2002-12-31 | $3.22 Million | $-23.23 Million | -7.207x | -1129.18% |
| 2001-12-31 | $24.11 Million | $-14.14 Million | -0.586x | -259.32% |
| 2000-12-31 | $38.74 Million | $-6.32 Million | -0.163x | +74.98% |
| 1999-12-31 | $6.90 Million | $-4.50 Million | -0.652x | -121.04% |
| 1998-12-31 | $-1.67 Million | $-5.17 Million | 3.099x | -5.86% |
| 1997-12-31 | $-926.26K | $-3.05 Million | 3.292x | -- |